Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Caverion Corporation – Managers' transactions – Crayfish BidCo Oy

Caverion Corporation Managers' transactions 28 November 2023 at 09:30 EETCaverion Corporation – Managers' transactions –  Crayfish BidCo Oy   Caverion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Crayfish BidCo Oy Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Mikael Aro Position: Member of the Board (2):Person Discharging Managerial Responsibilities In Issuer Name: Hans Petter Hjellestad Position:

Safello in collaboration with Lund University School of Economics and Management

Stockholm, 28 November 2023 | Safello, the leading crypto exchange in the Nordics, has entered into a partnership with Lund University School of Economics and Management for collaboration in conducting research within the field of cryptocurrencies.  The research will commence during the fall of 2024 and aims to reveal valuable insights in the field of cryptocurrencies. With extensive experience and deep knowledge of the industry, Safello is looking forward to contributing to the research and general understanding of the field, while continuing making crypto accessible to the wider mass.

New patent approvals for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has during the last months received four additional patent approval notifications. The Indian patent office Intellectual Property India has reported that Episurf has received two new granted patents in India. One is related to implant materials and coatings, while the other is related to Episurf’s damage visualisation process for surgical pre-planning and individualised medical device design. The Australian patent office IP Australia has issued a notice of acceptance for a patent related to the implant-specific drill used for Episurf’s implant technology.

Prolight’s CEO to BioStock: ”Proof-of-Performance in whole blood important milestone”

Prolight Diagnostics has demonstrated Proof-of-Performance in whole blood for its digital test system Psyros. It is already known that the system performs as promised for measuring troponin in serum, as well as thyroid-stimulating hormone in blood plasma. The latest results show that the system has equivalent performance in whole blood. BioStock reached out to the company's CEO Ulf Bladin to find out more.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/prolights-ceo-proof-of-performance-in-whole-blood-important-milestone This is a press release from BioStock -

Zalaris & Fremtind Forsikring celebrate the successful & seamless go-live of Zalaris PeopleHub in Norway

Zalaris, the provider of payroll and HR solutions that simplify work life and support creating sustainable businesses, celebrates the successful go-live of Zalaris PeopleHub to provide payroll and travel & expenses solutions and services to Fremtind Forsikring’s 1,000 employees in Norway.Fremtind  is one of Norway’s largest insurance companies and offers a complete range of insurance policies to the Norwegian market, covering all the customer’s insurance needs; personal, life, property, and things. Fremtind is built on more than 100 years of experience as an

AAX Biotech forms strategic collaboration with Oblique Therapeutics for therapeutic antibody development

Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is collaborating with Oblique Therapeutics, a biotech company developing new antibody medicines for severe diseases. This strategic collaboration will leverage AAX Biotech's proprietary epitope mapping technology, Seqitope™, to accelerate the advancement of Oblique Therapeutics' programs.The collaboration will commence with AAX Biotech applying its cutting-edge Seqitope™ technology to characterize antibody candidates of Oblique Therapeutics’ pain program targeting TRPV1, providing

Nordic Mining ASA: Cooperation on quartz in Norway

Nordic Mining ASA (“Nordic Mining” or the “Company”) is pleased to announce that the Company, through its wholly owned subsidiary Nordic Quartz AS, has entered into a Memorandum of Understanding (“MoU”) with a multinational minerals and metals company. The MoU is for a joint cooperation for exploration and development of a quartz deposit in the Kvinnherad municipality in Norway. The deposit in Kvinnherad host high purity hydrothermal quartz that may be developed into high-end products for the solar and micro-chip markets. The companies will jointly carry out various exploration

Repurchases of shares by Concentric AB during week 47, 2023

Between 20 November 2023 and 24 November 2023 Concentric AB (LEI code 5493002G9GMTKIP3PW19) (“Concentric”) has repurchased in total 28,312 own shares (ISIN: SE0003950864) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 3,519,172 own shares for a total maximum amount of SEK 150,000,000 that Concentric announced on 26 July 2023. The repurchase program, which runs between 31 July 2023 and 31 March 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission

Q3 and nine months report January – September 2023

Strengthened focus on NPLs and continued strong cash positionHighlights third quarter 2023 · Cash at the end of September 2023 was EUR 33.1m (52.3 at December 2022) · Agreement signed for acquisition of NPL portfolio in Romania with a gross collection value of over EUR 1 billion · Gross ERC at the end of September 2023 was EUR 246m (283 at December 2022) · Gross collections amounted to EUR 9.1m (23.2)* · Net collections amounted to EUR 8.1m (20.8)* · Cash EBITDA amounted to EUR 3.8m (17.3)* Highlights nine months 2023 · Gross collections amounted to EUR 39.4m (54.

Betolar and Metso to cooperate in the utilisation of side streams from the lithium hydroxide process

Betolar Plc Press release28.11.2023 Betolar and Metso to cooperate in the utilisation of side streams from the lithium hydroxide process Betolar and Metso have agreed on cooperation in which Betolar's technology can be offered globally to mining and refinery customers using Metso's lithium hydroxide process. With material technology solutions for Betolar's side stream research, the analcime sand generated as a side stream in lithium extraction is analysed and its further processing value is assessed. With Betolar's recipes, analcime sand can be utilised as gravel

Half-year Report

28 November 2023 Augmentum Fintech plc Interim Results for the six months ended 30 September 2023     Augmentum Fintech plc (LSE: AUGM) (“Augmentum” or the “Company”), Europe’s leading publicly listed fintech fund, announces its unaudited interim results for the six months ended 30 September 2023.   Financial highlights •  NAV per share after performance fee1 increased by 0.8% to 160.2p (31 March 2023: 158.9p). •  IRR of 16.6%2 on invested capital since inception (31 March 2023: 18.5%) •  Available cash at period end of £51.8 million (free cash of £48.0 million)

NOTICE OF EXTRAORDINARY GENERAL MEETING IN EDYOUTEC AB

The shareholders of edyoutec AB (publ), org.nr 559015-1360 ("edyoutec" or the "Company"), are hereby summoned to the Extraordinary General Meeting to be held on Friday 15 December 2023 at 14:00 at Advokatfirman Nerpin's office, Birger Jarlsgatan 2, 3rd floor in Stockholm.A. Right to participate and notification Shareholders who wish to participate in the Extra General Meeting must be recorded in the share register maintained by Euroclear Sweden AB ("Euroclear") as of Thursday, December 7, 2023, and must notify the company of their intention to participate no later than Friday, December 8,

EnQuest November Operations Update

EnQuest PLC, 28 November 2023 Operations update EnQuest Chief Executive, Amjad Bseisu, said: "The Group has continued to deliver good production performance from its operated assets and we expect full year production around the mid-point of our guidance range. This is under-pinned by the strong production uptime across the portfolio, including at Kraken following transformer upgrades, where we have seen 100% production efficiency since the reinstatement of full production during August. "Our 2023 drilling programme continues to progress well and remains on track to bring

Finns are worried about rising energy prices - positive movement in housing market

YIT Corporation Press release 28 November 2023 at 9:00 a.m.According to a survey* commissioned by YIT, the rising cost of living is a significant or very significant concern for 40 per cent of urban dwellers. Low-income households, tenants, and women under 36 are especially worried by the rising costs. The higher price of energy was the main concern among the respondents (67%). Homeowners were also concerned by increasing interest rates (45%) and the cost of future repairs (31%). The results also indicated that among those who moved last year, one in every five (22%) sought a more

New Sweco report: Rainfall Floods - Europe’s Critical Infrastructure Too Vulnerable

Recent devastating extreme rainfall events in Europe has led to significant monetary consequences. The new Critical Entities Resilience (CER) Directive  further highlights the need for resilient urban infrastructure. Sweco has conducted an extensive "Urban Insight" report on the vulnerability of critical infrastructure to climate risks. The study, which explored the policies and perspectives of 26 European cities, underscores the urgent need for comprehensive risk assessment and management to enhance the resilience of critical

Read original

Hexagon AB’s Nomination Committee proposes the election of two new independent Board Members

Hexagon AB's Nomination Committee proposes the election of Annika Falkengren and Ralph Haupter as new independent members of Hexagon's Board of Directors at the Annual General Meeting (AGM) on 29 April 2024. Annika Falkengren brings extensive expertise from a successful international career in the financial industry. Having led Skandinaviska Enskilda Banken (SEB) as President and CEO for more than a decade, Falkengren became Managing Partner at the Swiss private bank Lombard Odier in 2017. Based in Switzerland, Annika Falkengren will chair the Audit Committee upon joining the board of

Proact IT Group AB (publ) initiates a share repurchase program

The Board of Directors of Proact IT Group AB (“Proact”) has decided to initiate a share repurchase program by virtue of the authorisation granted by the Annual General Meeting held on May 4, 2023.Repurchases may be made on one or several occasions during the period up until the next Annual General Meeting. A maximum number of shares may be repurchased so that Proact’s total holding at any time does not exceed 10 percent of Proact’s total number of outstanding shares. Repurchases shall be made in accordance with Nasdaq Stockholm’s Rulebook for Issuers. Repurchases may only be effected at

Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose

· OX124 is based on Orexo´s world-class drug delivery platform, amorphOX®, and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl · Synthetic opioids are behind 91 percent of all fatal opioid overdoses in the US[1] · Prescription Drug User Fee Act date (PDUFA) set to July 15, 2024. If approved, US launch is expected to be initiated late 2024.   Uppsala, Sweden – November 28, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the New Drug Application (NDA) for OX124 has been accepted for review by the US Food and Drug

InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023

InDex Pharmaceuticals discontinues cobitolimod phase III program”This surprising and disappointing news confirms the complexity of the disease and the need for further research within this field, especially as moderate to severe ulcerative colitis is an indication with high unmet medical need for new treatment options. We are incredibly grateful to all the patients, investigators and study personnel for their engagement to date. We will conduct a comprehensive analysis of all the study data before announcing next steps,” said Jenny Sundqvist, CEO of InDex Pharmaceuticals. Period July –

Observe Medical – New order and distribution agreement with ReplantMed

Oslo, November 28, 2023 - Observe Medical ("the Company" or "Observe Medical") announces a new order and distribution agreement with ReplantMed, our Hungarian distributor. The UnoMeter portfolio is continuously expanding footprint with total orders from 15 countries, demonstrating its widespread market and global demand. Positive clinical evaluations further strengthen the quality and performance of the UnoMeter products across markets. “Our UnoMeter portfolio continue to gain traction and we are enthusiastic about consistently delivering high-quality products to our valued customers.

Proposed Combination with abrdn China Investment Company

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN,  INTO OR FROM THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA, ANY MEMBER STATE OF THE EEA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. This announcement is not an offer to sell, or a solicitation of an offer to acquire, securities in the United States or in any other jurisdiction in which the same would be unlawful. Neither

MindArk Interim Report Q3 2023

MindArk PE AB (publ) ("MindArk", the "Company") hereby announces that the Company's interim report for Q3 2023 has been published.Reporting periodThe report covers the period July 1 – September 30, 2023 and January 1 - September 30, 2023.  July 1 – September 30, 2023 Group figures. Comparative figures in parentheses refer to the same period last year. · Turnover amounted to 22.9 MSEK (21.4 MSEK)  · Capitalized work amounted to 6.1 MSEK (7 MSEK)  · Operating profit amounted to 1.8 MSEK (3.4 MSEK)  · Profit before tax amounted to 1.7 MSEK (-1.8 MSEK)  · Cash & cash

€40M strategic growth investment in leading decarbonization software platform for construction and manufacturing industries — One Click LCA announces investment from PSG and InfraVia

The investment will boost R&D, accelerate delivery of enterprise solutions, fund global expansion, and enable M&A — positioning One Click LCA as the definitive end-to-end sustainability software platform for construction and manufacturing.Helsinki (November 28th, 2023) One Click LCA , a world-leading decarbonization platform for the construction and manufacturing industries, today announces a €40M investment from PSG Equity (PSG), a leading growth equity

OBSERVE MEDICAL ASA – Commencement of the subscription period for the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 22 November 2023

There are no items matching the current filter
There are no more items matching the current filter
Back to top